❌

Reading view

A2DINOv3: Rethinking Multi-Modal Object Detection via Socialized Collaboration

arXiv:2608.21099v2 Announce Type: replace-cross Abstract: Multi-modal object detection is essential for robust scene understanding in challenging conditions, including low-light and adverse environments. Recent vision foundation models (e.g., DINOv3) have exhibited strong representation capabilities, yet adapting them to multi-modal scenarios remains challenging. Existing dense cross-modal fusion strategies often force heterogeneous modalities to interact indiscriminately, which may introduce redundant information and disrupt the valuable pre-trained representations. To address this issue, we revisit multi-modal fusion from the perspective of socialized learning and propose adapter to DINOv3 (A2DINOv3), a multi-expert collaboration framework with a Socialized Collaboration Protocol (SCP). Specifically, RGB and infrared branches are modeled as heterogeneous experts that independently preserve their specialized knowledge while exchanging complementary information through selective and constrained interactions. This design mitigates harmful cross-modal interference and prevents degradation of pre-trained priors during adaptation. Furthermore, a zero-initialization strategy is introduced to gradually activate cross-modal collaboration, enabling a smooth transition from modality-specific learning to cooperative representation learning. Extensive experiments on four multi-modal benchmarks, including aerial detection (GAIIC), autonomous driving (FLIR), low-light surveillance (LLVIP), and diverse real-world scenarios (M3FD), demonstrate that A2DINOv3 consistently achieves state-of-the-art performance in multi-modal object detection.
  •  

Multi-Omics-Enabled Precision Strategies for Overcoming CAR-T Therapy Limitations in Gastrointestinal Malignancies

Biofactors. 2026 Sep-Oct;52(5):e70150. doi: 10.1002/biof.70150.

ABSTRACT

Gastrointestinal malignancies, including gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma, remain major causes of cancer-related morbidity and mortality worldwide. Although chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, its efficacy in gastrointestinal solid tumors remains limited by antigen heterogeneity, insufficient trafficking and infiltration, immunosuppressive tumor microenvironments, on-target off-tumor toxicity, and adaptive resistance. In this review, we summarize the current landscape of CAR-T therapy in gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer, with a focus on representative target antigens and emerging biomarker strategies. We further discuss two major categories of biomarkers: target antigen-related biomarkers and conventional dynamic biomarkers, including serum tumor markers, cytokine changes, CAR-T expansion kinetics, and antigen-loss monitoring. In addition, we highlight how single-cell ribonucleic acid sequencing and spatial transcriptomics provide complementary insights into cellular states, immune exhaustion, stromal barriers, and spatially restricted immune exclusion. By integrating these multi-omics approaches with biomarker-guided patient stratification and next-generation CAR-T engineering, gastrointestinal solid tumor CAR-T therapy may evolve from empirical optimization toward mechanism-driven and precision-guided clinical translation.

PMID:42717494 | PMC:PMC13558850 | DOI:10.1002/biof.70150

  •  
❌